Navigation Links
Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
Date:9/6/2013

Oakland, CA (PRWEB) September 06, 2013

Dennis R. Hill, MD has confirmed today that he will be a panelist at the Third Annual Prostate Cancer Symposium titled “The Changing Paradigm of Prostate Cancer: Selective screening, Personalized Treatment and Survivorship in a Period of Rapid Progress.” The event will be Tuesday, September 17, from 5:30 to 8:30pm and is sponsored by the Alta Bates Summit Health Education Center. At this year’s symposium an expert panel of physicians and professionals address the newest treatment options for prostate cancer, and how to pro-actively address quality of life and health issues during and after treatment. Discussions will cover screening, watchful waiting, treatment technology, nutrition, physical fitness as well as possible side effects like incontinence and urinary issues.

Dr. Hill’s presentation will be on High Dose Rate Brachytherapy for prostate cancer treatment vs Surveillance. Dr. Hill comments, “There is a changing paradigm in prostate cancer on several fronts, including screening, diagnosis and treatment. It can be confusing. Hopefully, this panel will not only bring the latest information out, but also some common sense on how to approach this important cancer.” The other physician panelists will present “Rational Approach to Screening and Treatment Decisions in the Era of Genetic Assessment” and “The Urologist’s Perspective on Surveillance vs Treatment” and “The March towards Controlling Recurrent and Aggressive Prostate Cancer.” There will also be panelist presentations on enhancing survivorship quality by a nutritionist and a physical therapist.

Following the presentations there will be a question and answer session with the panelists. The event is open to the public and will be held at Alta Bates Summit Health Education Center, 400 Hawthorne Avenue, Oakland, CA 94609. Reservations are required. To reserve a seat call (510) 204-5804 or send an email to slaveni(at)sutterhealth(dot)org.

About Dennis R. Hill MD

Dr. Hill has been doing High Dose Rate Brachytherapy for prostate cancer treatment exclusively since 2004 and has published scholarly articles on the subject. His office is located at: Dennis R. Hill MD 3012 Summit Street Suite 2675 Oakland, CA 94609 510-869-8875 drh(at)dennisrhillmd(dot)com and his website is hdrprostatebrachytherapy.com, which includes a quiz to determine if a patient is a candidate for HDR Prostate Brachytherapy.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11086405.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
2. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
3. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
4. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Discusses Prostate Cancer Stage vs. Gleason Score
5. Dennis R. Hill, MD to be a Panelist at the Third Annual Prostate Cancer Symposium Focusing on the Changing Paradigm of Prostate Cancer
6. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
7. Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same
8. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
9. Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
10. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
11. Amgen Announces 2013 Third Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):